Nanoscale building blocks are individually exceptionally strong because they are close to ideal, defect-free materials. It is, however, difficult to retain the ideal properties in macroscale composites. Bottom-up assembly of a clay/polymer nanocomposite allowed for the preparation of a homogeneous, optically transparent material with planar orientation of the alumosilicate nanosheets. The stiffness and tensile strength of these multilayer composites are one order of magnitude greater than those of analogous nanocomposites at a processing temperature that is much lower than those of ceramic or polymer materials with similar characteristics. A high level of ordering of the nanoscale building blocks, combined with dense covalent and hydrogen bonding and stiffening of the polymer chains, leads to highly effective load transfer between nanosheets and the polymer.
Bacterial survival requires an intact peptidoglycan layer, a 3-dimensional exoskeleton that encapsulates the cytoplasmic membrane. Historically, the final steps of peptidoglycan synthesis are known to be carried out by d,d-transpeptidases, enzymes that are inhibited by the β-lactams which constitute >50% of all antibacterials in clinical use. Here, we show that the carbapenem subclass of β-lactams is distinctly effective not only because they inhibit d,d-transpeptidases and are poor substrates for β-lactamases, but primarily because they also inhibit non-classical transpeptidases, namely the l,d-transpeptidases, that generate the majority of linkages in the peptidoglycan of mycobacteria. We have characterized the molecular mechanisms responsible for inhibition of l,d-transpeptidases of M. tuberculosis and a range of bacteria, including ESKAPE pathogens, and utilized this information to design, synthesize and test simplified carbapenems with potent antibacterial activity.
The preparation of a high-strength and highly transparent nacre-like nanocomposite via layer-by-layer assembly technique from poly(vinyl alcohol) (PVA) and Na+-montmorillonite clay nanosheets is reported in this article. We show that a high density of weak bonding interactions between the polymer and the clay particles: hydrogen, dipole-induced dipole, and van der Waals undergoing break-reform deformations, can lead to high strength nanocomposites: sigmaUTS approximately 150 MPa and E' approximately 13 GPa. Further introduction of ionic bonds into the polymeric matrix creates a double network of sacrificial bonds which dramatically increases the mechanical properties: sigmaUTS approximately 320 MPa and E' approximately 60 GPa.
cAn effective regimen for treatment of tuberculosis (TB) is comprised of multiple drugs that inhibit a range of essential cellular activities in Mycobacterium tuberculosis. The effectiveness of a regimen is further enhanced if constituent drugs act with synergy. Here, we report that faropenem (a penem) or biapenem, doripenem, or meropenem (carbapenems), which belong to the -lactam class of antibiotics, and rifampin, one of the drugs that forms the backbone of TB treatment, act with synergy when combined. One of the reasons (carba)penems are seldom used for treatment of TB is the high dosage levels required, often at the therapeutic limits. The synergistic combination of rifampin and these (carba)penems indicates that (carba)penems can be administered at dosages that are therapeutically relevant. The combination of faropenem and rifampin also limits the frequency of resistant mutants, as we were unable to obtain spontaneous mutants in the presence of these two drugs. The combinations of rifampin and (carba)penems were effective not only against drug-sensitive Mycobacterium tuberculosis but also against drugresistant clinical isolates that are otherwise resistant to rifampin. A combination of doripenem or biapenem and rifampin also exhibited synergistic activity against Mycobacterium abscessus. Although the MICs of these three drugs alone against M. abscessus are too high to be of clinical relevance, their concentrations in combinations are therapeutically relevant; therefore, they warrant further evaluation for clinical utility to treat Mycobacterium abscessus infection, especially in cystic fibrosis patients.
Aim:The objective of this study was to assess if avibactam, a new β-lactamase inhibitor, can restore the potency of carbapenems, a sub-class of β-lactams, against Mycobacterium abscessus clinical isolates. Materials & methods: 28 M. abscessus clinical isolates that are resistant to multiple drugs currently used to treat its infection were included. MIC of carbapenems alone and in combination with avibactam against these strains were determined. Results: Tebipenem, an oral carbapenem, and ertapenem and panipenem exhibited the greatest shift in MIC when supplemented with avibactam. Conclusion: Avibactam restores MICs of tebipenem, ertapenem and panipenem against M. abscessus to therapeutically achievable concentrations and raises the possibility of usefulness of these carbapenems to treat drug-resistant M. abscessus infections. Mycobacterium abscessus is a rapidly growing nontuberculous mycobacterium found widely in soil and water and can cause a spectrum of infections [1]. Prevalence of M. abscessus infections in the lungs of people with chronic conditions, such as cystic fibrosis is significant and can often lead to serious morbidity [2]. A survey revealed that M. abscessus is present in the sputum of approximately 13% of cystic fibrosis patients in the USA [3]. Among nontuberculous mycobacterium lung infections, M. abscessus is one of the prevalent species and often leads to a chronic and incurable disease [4][5][6]. Drug resistance in M. abscessus is steadily rising globally, making it increasingly difficult to manage infections with these strains [7]. Therefore, new drugs and novel regimens are acutely needed to treat infections with M. abscessus. An ideal new drug would inhibit a novel target so that it can be effective against M. abscessus strains that are resistant to currently used drugs.The peptidoglycan is an Achilles' heel of bacteria as agents that inhibit its biosynthesis, namely β-lactams and glycopeptides, comprise some of the most widely used class of antibacterials in modern medicine. β-lactams derive their activity by preventing formation of linkage between peptide side chains by inhibiting the transpeptidases that catalyze this reaction [8]. Recently it was demon strated that majority of the linkages in the peptidoglycan layer of M. abscessus are generated by LD-transpeptidases [9] and that this class of enzyme is selectively more susceptible to the carbapenem class of β-lactams [10][11][12]. Imipenem, a carbapenem, has superior activity compared with For reprint orders, please contact: reprints@futuremedicine.com
Tigecycline is used in multidrug regimens for salvage therapy of Mycobacterium abscessus infections but is often poorly tolerated and has no oral formulation. Here, we report similar in vitro activity of two newly approved tetracycline analogs, omadacycline and eravacycline, against 28 drug-resistant clinical isolates of M. abscessus complex. Since omadacycline and eravacycline appear to be better tolerated than tigecycline and since omadacycline is also formulated for oral dosing, these tetracycline analogs may represent new treatment options for M. abscessus infections.
Layer-by-layer assembly (LBL) can generate unique materials with high degrees of nanoscale organization and excellent mechanical, electrical, and optical properties. The typical nanometer scale thicknesses restrict their utility to thin films and coatings. Preparation of macroscale nanocomposites will indicate a paradigm change in the practice of LBL, materials manufacturing, and multiscale organization of nanocomponents. Such materials were made in this study via consolidation of individual LBL sheets from polyurethane. Substantial enhancement of mechanical properties after consolidation was observed. The resulting laminates are homogeneous, transparent, and highly ductile and display nearly 3x higher strength and toughness than their components. Hierarchically organized composites combining structural features from 1 to 1 000 000 nm at six different levels of dimensionality with a high degree of structural control at every level can be obtained. The functionality of the resulting fluorescent sandwiches of different colors makes possible mechanical deformation imaging with submicrometer resolution in real time and 3D capabilities.
Nanoscale control of structure in polymer nanocomposites is critical for their performance but has been difficult to investigate systematically due to the lack of a suitable experimental model. In this work, we investigated the role of nanoparticle layer separation in the finite deformation response of layered polyurethane-(PU-) montmorillonite (MTM) nanocomposites. A series of multilayered nanocomposites was manufactured, with alternating PU and MTM nanolayers, using a layer-by-layer manufacturing technique. The systematic variation in MTM nanoparticle volume fraction was achieved by varying the thickness of the PU nanolayer and therefore the MTM layer separation. Traditional polymer nanocomposite blending techniques result in a wide variation in nanoparticle separation for a given nanocomposite. In this investigation, we controlled the MTM nanoparticle layer separation, which allowed us to examine its effect on the nanocomposite response over a broad range in nanoparticle volume fraction. The PU-MTM nanocomposites demonstrated an increasing yield strength and stiffness with increased MTM volume fraction or reduced nanoparticle layer separation. A transition from ductile to brittle behavior in the stress-strain constitutive response was observed at a high volume fraction of MTM nanoparticles. We demonstrate that a critical nanoparticle separation exists, below which brittle behavior dominates the response of PU-MTM nanocomposites.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.